AAPL313.33+0.92 (+0.29%) ▲|ABBV246.04+2.17 (+0.89%) ▲|ABT107.81-0.15 (-0.14%) ▼|ACN175.72+4.61 (+2.69%) ▲|ADBE265.21+4.97 (+1.91%) ▲|AMAT539.14+11.66 (+2.21%) ▲|AMD483.36-5.92 (-1.21%) ▼|AMGN410.95+6.10 (+1.51%) ▲|AMT172.54+1.34 (+0.78%) ▲|AMZN274.48+2.22 (+0.82%) ▲|AVGO427.76+7.20 (+1.71%) ▲|AXP340.91-1.69 (-0.49%) ▼|BA234.42+2.23 (+0.96%) ▲|BAC63.17+0.17 (+0.27%) ▲|BKNG214.42+7.03 (+3.39%) ▲|BLK1,136.39+7.09 (+0.63%) ▲|BMY64.72+0.57 (+0.89%) ▲|BNY157.61-1.21 (-0.76%) ▼|BRK-B521.80-2.81 (-0.54%) ▼|C135.00+1.18 (+0.88%) ▲|CAT842.19-14.77 (-1.72%) ▼|CL93.27+0.27 (+0.29%) ▲|CMCSA25.36+0.19 (+0.75%) ▲|COF217.76-2.24 (-1.02%) ▼|COP117.61+0.85 (+0.73%) ▲|COST947.82-1.33 (-0.14%) ▼|CRM192.74+5.97 (+3.20%) ▲|CSCO121.43+0.55 (+0.46%) ▲|CVS95.70-0.52 (-0.54%) ▼|CVX186.56-2.67 (-1.41%) ▼|DE620.83+5.99 (+0.97%) ▲|DHR204.76+4.78 (+2.39%) ▲|DIS104.91+0.23 (+0.22%) ▲|DUK124.85+0.95 (+0.77%) ▲|EMR158.26+1.35 (+0.86%) ▲|FDX318.57+2.70 (+0.85%) ▲|GD392.05+5.13 (+1.33%) ▲|GE370.08-4.47 (-1.19%) ▼|GEV990.32-9.98 (-1.00%) ▼|GILD133.21+2.35 (+1.80%) ▲|GM87.58+0.64 (+0.74%) ▲|GOOG353.47-3.15 (-0.88%) ▼|GOOGL354.30-3.45 (-0.96%) ▼|GS1,039.61+7.03 (+0.68%) ▲|HD355.62+6.10 (+1.75%) ▲|HON246.21+5.47 (+2.27%) ▲|IBM237.28+3.85 (+1.65%) ▲|INTC101.65+1.84 (+1.84%) ▲|INTU325.25+3.34 (+1.04%) ▲|ISRG378.81+5.10 (+1.36%) ▲|JNJ259.24+2.26 (+0.88%) ▲|JPM357.52+1.22 (+0.34%) ▲|KO87.05+0.20 (+0.23%) ▲|LIN489.98-0.13 (-0.03%) ▼|LLY1,185.71-6.23 (-0.52%) ▼|LMT587.95+5.10 (+0.88%) ▲|LOW223.35+4.95 (+2.27%) ▲|LRCX311.35+5.58 (+1.82%) ▲|MA562.95-13.00 (-2.26%) ▼|MCD274.48-1.78 (-0.64%) ▼|MDLZ62.61-0.14 (-0.22%) ▼|MDT87.16+1.24 (+1.44%) ▲|META592.10+2.20 (+0.37%) ▲|MMM182.90+2.19 (+1.21%) ▲|MO68.35+0.60 (+0.89%) ▲|MRK128.58+0.21 (+0.16%) ▲|MS216.33+2.58 (+1.21%) ▲|MSFT499.99+0.13 (+0.03%) ▲|MU877.57-3.90 (-0.44%) ▼|NEE84.65+0.05 (+0.06%) ▲|NFLX74.14+0.45 (+0.61%) ▲|NKE41.70-0.30 (-0.71%) ▼|NOW124.88+7.53 (+6.42%) ▲|NVDA223.96+4.97 (+2.27%) ▲|ORCL147.02+3.55 (+2.47%) ▲|PEP139.02+0.58 (+0.42%) ▲|PFE26.76+0.56 (+2.14%) ▲|PG145.79-1.18 (-0.80%) ▼|PLTR172.01+16.09 (+10.32%) ▲|PM189.57+1.52 (+0.81%) ▲|QCOM167.86+7.47 (+4.66%) ▲|RTX223.03-0.22 (-0.10%) ▼|SBUX105.58+0.42 (+0.40%) ▲|SCHW107.60-0.06 (-0.06%) ▼|SO92.69-0.21 (-0.23%) ▼|SPG222.91+1.08 (+0.49%) ▲|T23.79+0.08 (+0.34%) ▲|TMO594.00+13.98 (+2.41%) ▲|TMUS177.19-2.78 (-1.54%) ▼|TSLA328.58+9.05 (+2.83%) ▲|TXN286.08+7.68 (+2.76%) ▲|UBER75.02+4.55 (+6.46%) ▲|UNH407.08+3.11 (+0.77%) ▲|UNP293.13-2.25 (-0.76%) ▼|UPS104.50+1.30 (+1.26%) ▲|USB63.94+0.13 (+0.20%) ▲|V362.50-7.97 (-2.15%) ▼|VZ47.06+0.07 (+0.15%) ▲|WFC87.25+0.16 (+0.18%) ▲|WMT111.85-0.22 (-0.20%) ▼|XOM153.04-1.80 (-1.16%) ▼|AAPL313.33+0.92 (+0.29%) ▲|ABBV246.04+2.17 (+0.89%) ▲|ABT107.81-0.15 (-0.14%) ▼|ACN175.72+4.61 (+2.69%) ▲|ADBE265.21+4.97 (+1.91%) ▲|AMAT539.14+11.66 (+2.21%) ▲|AMD483.36-5.92 (-1.21%) ▼|AMGN410.95+6.10 (+1.51%) ▲|AMT172.54+1.34 (+0.78%) ▲|AMZN274.48+2.22 (+0.82%) ▲|AVGO427.76+7.20 (+1.71%) ▲|AXP340.91-1.69 (-0.49%) ▼|BA234.42+2.23 (+0.96%) ▲|BAC63.17+0.17 (+0.27%) ▲|BKNG214.42+7.03 (+3.39%) ▲|BLK1,136.39+7.09 (+0.63%) ▲|BMY64.72+0.57 (+0.89%) ▲|BNY157.61-1.21 (-0.76%) ▼|BRK-B521.80-2.81 (-0.54%) ▼|C135.00+1.18 (+0.88%) ▲|CAT842.19-14.77 (-1.72%) ▼|CL93.27+0.27 (+0.29%) ▲|CMCSA25.36+0.19 (+0.75%) ▲|COF217.76-2.24 (-1.02%) ▼|COP117.61+0.85 (+0.73%) ▲|COST947.82-1.33 (-0.14%) ▼|CRM192.74+5.97 (+3.20%) ▲|CSCO121.43+0.55 (+0.46%) ▲|CVS95.70-0.52 (-0.54%) ▼|CVX186.56-2.67 (-1.41%) ▼|DE620.83+5.99 (+0.97%) ▲|DHR204.76+4.78 (+2.39%) ▲|DIS104.91+0.23 (+0.22%) ▲|DUK124.85+0.95 (+0.77%) ▲|EMR158.26+1.35 (+0.86%) ▲|FDX318.57+2.70 (+0.85%) ▲|GD392.05+5.13 (+1.33%) ▲|GE370.08-4.47 (-1.19%) ▼|GEV990.32-9.98 (-1.00%) ▼|GILD133.21+2.35 (+1.80%) ▲|GM87.58+0.64 (+0.74%) ▲|GOOG353.47-3.15 (-0.88%) ▼|GOOGL354.30-3.45 (-0.96%) ▼|GS1,039.61+7.03 (+0.68%) ▲|HD355.62+6.10 (+1.75%) ▲|HON246.21+5.47 (+2.27%) ▲|IBM237.28+3.85 (+1.65%) ▲|INTC101.65+1.84 (+1.84%) ▲|INTU325.25+3.34 (+1.04%) ▲|ISRG378.81+5.10 (+1.36%) ▲|JNJ259.24+2.26 (+0.88%) ▲|JPM357.52+1.22 (+0.34%) ▲|KO87.05+0.20 (+0.23%) ▲|LIN489.98-0.13 (-0.03%) ▼|LLY1,185.71-6.23 (-0.52%) ▼|LMT587.95+5.10 (+0.88%) ▲|LOW223.35+4.95 (+2.27%) ▲|LRCX311.35+5.58 (+1.82%) ▲|MA562.95-13.00 (-2.26%) ▼|MCD274.48-1.78 (-0.64%) ▼|MDLZ62.61-0.14 (-0.22%) ▼|MDT87.16+1.24 (+1.44%) ▲|META592.10+2.20 (+0.37%) ▲|MMM182.90+2.19 (+1.21%) ▲|MO68.35+0.60 (+0.89%) ▲|MRK128.58+0.21 (+0.16%) ▲|MS216.33+2.58 (+1.21%) ▲|MSFT499.99+0.13 (+0.03%) ▲|MU877.57-3.90 (-0.44%) ▼|NEE84.65+0.05 (+0.06%) ▲|NFLX74.14+0.45 (+0.61%) ▲|NKE41.70-0.30 (-0.71%) ▼|NOW124.88+7.53 (+6.42%) ▲|NVDA223.96+4.97 (+2.27%) ▲|ORCL147.02+3.55 (+2.47%) ▲|PEP139.02+0.58 (+0.42%) ▲|PFE26.76+0.56 (+2.14%) ▲|PG145.79-1.18 (-0.80%) ▼|PLTR172.01+16.09 (+10.32%) ▲|PM189.57+1.52 (+0.81%) ▲|QCOM167.86+7.47 (+4.66%) ▲|RTX223.03-0.22 (-0.10%) ▼|SBUX105.58+0.42 (+0.40%) ▲|SCHW107.60-0.06 (-0.06%) ▼|SO92.69-0.21 (-0.23%) ▼|SPG222.91+1.08 (+0.49%) ▲|T23.79+0.08 (+0.34%) ▲|TMO594.00+13.98 (+2.41%) ▲|TMUS177.19-2.78 (-1.54%) ▼|TSLA328.58+9.05 (+2.83%) ▲|TXN286.08+7.68 (+2.76%) ▲|UBER75.02+4.55 (+6.46%) ▲|UNH407.08+3.11 (+0.77%) ▲|UNP293.13-2.25 (-0.76%) ▼|UPS104.50+1.30 (+1.26%) ▲|USB63.94+0.13 (+0.20%) ▲|V362.50-7.97 (-2.15%) ▼|VZ47.06+0.07 (+0.15%) ▲|WFC87.25+0.16 (+0.18%) ▲|WMT111.85-0.22 (-0.20%) ▼|XOM153.04-1.80 (-1.16%) ▼|
23.2 C
New York
Saturday, August 8, 2026

Tag: CA4990531069

newssourceFORcompanyinformationcontent1releasesmarket

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“APA”) entered with Paladin Pharma Inc., an Endo, Inc. operating company, as announced in March 2025.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCA4990531069

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers